Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema - Slideshow (NASDAQ:PHVS) 2025-12-09
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
Leerink Partners, olumlu klinik deney sonuçları sonrası Pharvaris hisse fiyat hedefini 38 dolara yükseltti